Beyond CD19 CAR-T cells in lymphoma

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 has revolutionized treatment for relapsed/refractory B-cell malignancies.
• Despite high remission rates, CD19-specific CAR-T therapy is limited to B-cell cancers and susceptible to tumor escape via antigen loss.

Purpose of the Study:

• To review emerging CAR-T cell targets beyond CD19.
• To discuss strategies for overcoming CD19 antigen loss and expanding CAR-T applications to other hematologic malignancies like Hodgkin and T-cell lymphomas.

Main Methods:

• Literature review of recent clinical trials.
• Analysis of CAR-T cell targets beyond CD19.
• Evaluation of strategies to overcome antigen escape.

Main Results:

• Several alternative targets are under investigation in clinical trials.
• New targets aim to address resistance mechanisms, including CD19 antigen loss.
• CAR-T cell therapy is being explored for Hodgkin and T-cell lymphomas.

Conclusions:

• Exploring targets beyond CD19 is crucial for enhancing CAR-T therapy efficacy and broadening its application.
• Overcoming antigen loss and treating non-B-cell lymphomas are key areas of ongoing research.